Mathematical description of the effect of HIF inhibition on the radiobiological response of LNCaP cells

Azorín-Vega, Erika; León, Consuelo Letechipía de; García-Reyna, Mayra Guadalupe; Vega-Carrillo, Héctor René

doi:10.1016/j.apradiso.2022.110157

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the preliminary stages of research, small interfering RNA (siRNA) technology was used to knock down HIF-1 in PC-3 cells, revealing its effect on radiation sensitization [ 134 ]. Hormone-sensitive PCa LNCaP cells can also be treated with a HIF-1 inhibitor [ 135 ]. As our understanding of the underlying mechanisms of these processes grows, studies have demonstrated that HIF-1 expression in PCa cells can facilitate DNA repair and induce radiotherapy resistance by activating gene expression along the NHEJ-related pathway and facilitating the nuclear translocation of β-catenin [ 136 ].…”

Section: Hypoxia In Tumor Corementioning

confidence: 99%

Uncovering the Secrets of Prostate Cancer’s Radiotherapy Resistance: Advances in Mechanism Research

et al. 2023

View full text Add to dashboard Cite

Prostate cancer (PCa) is a critical global public health issue with its incidence on the rise. Radiation therapy holds a primary role in PCa treatment; however, radiation resistance has become increasingly challenging as we uncover more about PCa’s pathogenesis. Our review aims to investigate the multifaceted mechanisms underlying radiation therapy resistance in PCa. Specifically, we will examine how various factors, such as cell cycle regulation, DNA damage repair, hypoxic conditions, oxidative stress, testosterone levels, epithelial–mesenchymal transition, and tumor stem cells, contribute to radiation therapy resistance. By exploring these mechanisms, we hope to offer new insights and directions towards overcoming the challenges of radiation therapy resistance in PCa. This can also provide a theoretical basis for the clinical application of novel ultra-high-dose-rate (FLASH) radiotherapy in the era of PCa.

show abstract

Section: Hypoxia In Tumor Corementioning

confidence: 99%